Molecular Pharmacology and Experimental Therapeutics (MPET)

Institute of Biomedicine (IBUB)

MPET Lab

Dept. of Biochemistry and Molecular Biomedicine

Av. Diagonal, 643

08028 Barcelona

Phone: +34 934031543 / +34 934021544
www.ciberehd.org/

 

Principal investigator: Dr. Marçal Pastor-Anglada Senior scientist: Dr. Sandra Pérez-Torras  Senior post-doc: Dr. Nerea Urtasun Plans Post-doc researchers: Dr. Aida Mata Ventosa • Dr.  Liska Caviedes Cárdenas • Dr. José Antonio Agüero Fernández • Dr. Laura García Rivas Ph.D. Students: Andrea Prieto Industrial Ph.D. student: Eloy Pena

Share on whatsapp
Share on facebook
Share on twitter
Share on linkedin
Share on telegram

Current
Research

The MPET laboratory is a worldwide reference in the field of nucleoside metabolism, and in particular in the study of the biology and pharmacology of Nucleoside Transporter (NT) proteins. We have focused on the molecular basis of inter-individual genetic variability in drug-transporter interactions (transporter pharmacogenetics) as well as on the impact of transporters on nucleotide metabolism and disease. Current major research at the MPET laboratory focuses on:

-The study of the gene and protein networks incorporating transporter-related proteins (the so-called “transportome”) for a better understanding of the mechanisms behind the pathogenesis of different types of cancer (solid tumors and lymphoproliferative malignancies).

-The analysis of the NT protein interactome (protein-protein interactions and networks) as a way to understand how these proteins are connected to nucleotide metabolism.

-The study of metabolic reprogramming during the oncogenic process, particularly focusing on the regulation of nucleotide metabolism to identify biomarkers and new druggable targets

-The role of NT proteins on purinergic regulation in inflammation and cancer.

-The role of membrane transporters in the mechanism of action of novel drugs and the impact of transporter genetic variability on drug-transporter and drug-drug transporter interactions to better understand pharmacogenetics-based differences in drug action.

-Cellular and in vivo models for the preclinical characterization of novel anticancer drugs.

Selected
Publications

Perelló-Reus, C.M.; Català, A.; Caviedes-Cárdenas, L.; Vega-García, N.; Camós, M.; Pérez-Torras, S.; Pastor-Anglada, M. FMS-like tyrosine kinase 3 (FLT3) modulates key enzymes of nucleotide metabolism implicated in cytarabine responsiveness in pediatric acute leukemia. Pharmacol Res. 2020 Jan; 151:104556. doi:10.1016/j.phrs.2019.104556.

Pérez-Torras, S.; Mata-Ventosa, A.; Drögemöller, B.; Tarailo-Graovac, M.; Meijer, J.; Meinsma, R.; van Cruchten, A.G.; Kulik, W.; Viel-Oliva, A.; Bidon-Chanal, A.; Ross, C.J.; Wassermann, W.W.; van Karnebeek, C.D.M.; Pastor-Anglada, M.; van Kuilenburg, A.B.P. Deficiency of perforin and hCNT1, a novel inborn error of pyrimidine metabolism, associated with a rapidly developing lethal phenotype due to multi-organ failure. BBA Mol. Basis Dis. 2019, in press. doi: 10.1016/j.bbadis.2019.01.013.

Pastor-Anglada, M.; Urtasun, N.; Pérez-Torras, S. Intestinal nucleoside transporters: function, expression, and regulation. Compr. Physiol. 8:1003-1017, 2018. doi: 10.1002/cphy.c170039.

Urtasun, N.; Boces-Pascual, C.; Boix, L.; Bruix, J.; Pastor-Anglada, M.: Pérez-Torras, S. Role of drug-dependent transporter modulation on the chemosensitivity of cholangiocarcinoma. Oncotarget. 8:90185-90196, 2017. doi:10.18632/oncotarget.21624.

Arimany-Nardi, C.; Claudio-Montero, A.; Viel-Oliva, A.; Schmidtke, P.; Estarellas, C.; Barril, X.; Bidon-Chanal, A.; Pastor-Anglada, M. Identification and characterization of a secondary sodium-binding site and the main selectivity determinants in the human Concentrative Nucleoside Transporter 3. Mol. Pharm. 14:1980-1987, 2017. doi: 10.1021/acs.molpharmaceut.7b00085.

Selected
Publications